CYP1A1 genetic polymorphism is a promising predictor to improve chemotherapy effects in patients with metastatic breast cancer treated with docetaxel plus thiotepa vs. docetaxel plus capecitabine
- 327 Downloads
A prospective study was performed to compare the outcome for metastatic breast cancer (MBC) patients treated with docetaxel plus thiotepa (DT) or docetaxel plus capecitabine (DC), and to explore the value of CYP1A1*2C polymorphisms in predicting clinical efficacy of these chemotherapies.
MBC patients (n = 130) were randomized to treatment with DT (n = 65) or DC (n = 65). Response rate, disease control rate, progression-free and overall survival were monitored. Genotyping of CYP1A1*2C was performed in all patients.
DT and DC produced similar overall disease control rates (76.9 vs 69.2%), median PFS (6.7 vs. 7.5 months) and OS (20.1 vs. 21.0 months) (P > 0.05 for all comparisons); however, DT exhibited a higher rate of control of localized liver metastases (78.6 vs 41.2%, P = 0.023). Among patients homozygous for wild-type CYP1A1*1 genotype (AA), DT treatment was associated with a significantly longer PFS (8.4 vs. 6.4 months, P = 0.019) and OS (33.4 vs. 15.8 months, P = 0.018). Conversely, among patients carrying the variant CYP1A1*2C genotype (AG/GG), DC treatment was associated with a significantly longer PFS (8.4 vs. 5.5 month, P = 0.005), and OS (28.5 vs. 19.6 months, P = 0.010). After adjusting for competing risk factors, CYP1A1*2C genotype was confirmed to be an independent predictor of PFS and OS for each chemotherapy combination.
Overall, DT and DC result in similar clinical efficacy for MBC patients; however, efficacy for each therapy differs depending on CYP1A1*2C genotype.
KeywordsCYP1A1 Single nucleotide polymorphism Breast cancer Liver metastasis Docetaxel Thiotepa Capecitabine
Compliance with ethical standards
This study was funded by Susan G Komen for Cure Foundation (no. SPCHIN1201), Youth Foundation of Beijing Shijitan Hospital of Capital Medical University (no. 2013-q-04) and China Railway Corporation Research Project (2016-A44).
Conflict of interest
The authors declared that they have no conflicts of interest related to this work.
All procedures performed in this study were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Informed consent was obtained from all individual participants included in the study.
- 6.Gradishar WJ, Anderson BO, Balassanian R, Blair SL, Burstein HJ, Cyr A, Elias AD, Farrar WB, Forero A, Giordano SH, Goetz M, Goldstein LJ, Hudis CA, Isakoff SJ, Marcom PK, Mayer IA, McCormick B, Moran M, Patel SA, Pierce LJ, Reed EC, Salerno KE, Schwartzberg LS, Smith KL, Smith ML, Soliman H, Somlo G, Telli M, Ward JH, Shead DA, Kumar R (2015) NCCN guidelines insights breast cancer, Version 1.2016. J Natl Compr Canc Netw 13(12):1475–1485CrossRefPubMedGoogle Scholar
- 7.Dong N, Yu J, Wang C, Zheng X, Wang Z, Di L, Song G, Zhu B, Che L, Jia J, Jiang H, Zhou X, Wang X, Ren J (2012) Pharmacogenetic assessment of clinical outcome in patients with metastatic breast cancer treated with docetaxel plus capecitabine. J Cancer Res Clin Oncol 138(7):1197–1203. https://doi.org/10.1007/s00432-012-1183-5 CrossRefPubMedGoogle Scholar
- 8.Thiotepa (2011). Report on carcinogens. Carcinog Profiles 12:406–407Google Scholar
- 10.Berry DA, Ueno NT, Johnson MM, Lei X, Caputo J, Rodenhuis S, Peters WP, Leonard RC, Barlow WE, Tallman MS, Bergh J, Nitz UA, Gianni AM, Basser RL, Zander AR, Coombes RC, Roche H, Tokuda Y, de Vries EG, Hortobagyi GN, Crown JP, Pedrazzoli P, Bregni M, Demirer T (2011) High-dose chemotherapy with autologous stem-cell support as adjuvant therapy in breast cancer: overview of 15 randomized trials. J Clin Oncol 29(24):3214–3223. https://doi.org/10.1200/JCO.2010.32.5910 CrossRefPubMedPubMedCentralGoogle Scholar
- 11.Rodenhuis S, Bontenbal M, van Hoesel QG, Smit WM, Nooij MA, Voest EE, van der Wall E, Hupperets P, van Tinteren H, Peterse JL, van de Vijver MJ, de Vries EG, Netherlands Working Party on Autologous Transplantation in Solid T (2006) Efficacy of high-dose alkylating chemotherapy in HER2/neu-negative breast cancer. Ann Oncol 17 (4):588–596. https://doi.org/10.1093/annonc/mdl001 CrossRefPubMedGoogle Scholar
- 12.Wang X, Ren J, Zhang J, Yan Y, Jiang N, Yu J, Di L, Song G, Che L, Jia J, Zhou X,Yang H, Lyerly HK (2016) Prospective study of cyclophosphamide, thiotepa, carboplatin combined with adoptive DC-CIK followed by metronomic cyclophosphamide therapy as salvage treatment for triple negative metastatic breast cancers patients (aged < 45). Clin Trans Oncol 18 (1):82–87. https://doi.org/10.1007/s12094-015-1339-2 CrossRefGoogle Scholar
- 14.Lu Z, Jia J, Di L, Song G, Yuan Y, Ma B, Yu J, Zhu Y, Wang X, Zhou X, Ren J (2011) DNA methyltransferase inhibitor CDA-2 synergizes with high-dose thiotepa and paclitaxel in killing breast cancer stem cells. Front Biosci (Elite Ed) 3:240–249Google Scholar
- 15.Ren J, Di L, Song G, Yu J, Jia J, Zhu Y, Yan Y, Jiang H, Liang X, Che L, Zhang J, Wan F, Wang X, Zhou X, Lyerly HK (2013) Selections of appropriate regimen of high-dose chemotherapy combined with adoptive cellular therapy with dendritic and cytokine-induced killer cells improved progression-free and overall survival in patients with metastatic breast cancer: reargument of such contentious therapeutic preferences. Clin Trans Oncol 15(10):780–788. https://doi.org/10.1007/s12094-013-1001-9 CrossRefGoogle Scholar
- 16.Yu J, Lj DI, Song G, Che L, Jiang H, Zhu Y, Liang X, Jia J, Zhang J, Yang H, Wang X, Zhou X, Ren J (2011) Randomized clinical case-control trial for the comparison of docetaxel plus thiotepa versus docetaxel plus capecitabine in patients with metastatic breast cancer. Beijing Da Xue Xue Bao 43(1):151–156PubMedGoogle Scholar
- 17.Song Q, Zhou X, Yu J, Dong N, Wang X, Yang H, Ren J, Lyerly HK (2015) The prognostic values of CYP2B6 genetic polymorphisms and metastatic sites for advanced breast cancer patients treated with docetaxel and thiotepa. Sci Rep 5:16775. https://doi.org/10.1038/srep16775 CrossRefPubMedPubMedCentralGoogle Scholar
- 18.Zhou X, Wang X, Song Q, Yang H, Zhu X, Yu J, Song G, Di L, Ren J, Shao H, Lyerly HK (2015) Transformation of alkylating regimen of thiotepa into tepa determines the disease progression through GSTP1 gene polymorphism for metastatic breast cancer patients receiving thiotepa containing salvage chemotherapy. Int J Clin Pharmacol Ther 53(11):914–922. https://doi.org/10.5414/CP202391 CrossRefPubMedGoogle Scholar
- 19.Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92(3):205–216CrossRefPubMedGoogle Scholar
- 20.de Kock I, Mirhosseini M, Lau F, Thai V, Downing M, Quan H, Lesperance M, Yang J (2013) Conversion of Karnofsky Performance Status (KPS) and Eastern Cooperative Oncology Group Performance Status (ECOG) to Palliative Performance Scale (PPS), and the interchangeability of PPS and KPS in prognostic tools. J Palliat Care 29(3):163–169PubMedGoogle Scholar
- 21.O’Shaughnessy J, Miles D, Vukelja S, Moiseyenko V, Ayoub JP, Cervantes G, Fumoleau P, Jones S, Lui WY, Mauriac L, Twelves C, Van Hazel G, Verma S, Leonard R (2002) Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 20(12):2812–2823. https://doi.org/10.1200/JCO.2002.09.002 CrossRefPubMedGoogle Scholar
- 22.Li J, You J, Si W, Zhu Y, Chen Y, Yang B, Han C, Linghu R, Zhang X, Jiao S, Yang J (2015) Docetaxel/S-1 versus docetaxel/capecitabine as first-line treatment for advanced breast cancer: a retrospective study. Medicine (Baltimore) 94(41):e1340. https://doi.org/10.1097/MD.0000000000001340 CrossRefGoogle Scholar
- 23.John M, Hinke A, Stauch M, Wolf H, Mohr B, Hindenburg HJ, Papke J, Schlosser J, Group FS (2012) Weekly paclitaxel plus trastuzumab in metastatic breast cancer pretreated with anthracyclines—a phase II multipractice study. BMC cancer 12:165. https://doi.org/10.1186/1471-2407-12-165 CrossRefPubMedPubMedCentralGoogle Scholar
- 24.Fabi A, Giannarelli D, Malaguti P, Ferretti G, Vari S, Papaldo P, Nistico C, Caterino M, De Vita R, Mottolese M, Iacorossi L, Cognetti F (2015) Prospective study on nanoparticle albumin-bound paclitaxel in advanced breast cancer: clinical results and biological observations in taxane-pretreated patients. Drug Des Devel Ther 9:6177–6183. https://doi.org/10.2147/DDDT.S89575 CrossRefPubMedPubMedCentralGoogle Scholar
- 25.Vici P, Fabi A, Metro G, Sergi D, Giannarelli D, Di Lauro L, Bepler G, Tomao F, Cognetti F, Conti F, Lopez M (2011) Phase I–II trial of prolonged gemcitabine infusion plus paclitaxel as a biweekly schedule for advanced breast cancer patients pretreated with anthracyclines. Cancer Chemother Pharmacol 67(3):687–693. https://doi.org/10.1007/s00280-010-1369-y CrossRefPubMedGoogle Scholar
- 27.Venur VA, Leone JP (2016) Targeted therapies for brain metastases from breast cancer. Int J Mol Sci 17 (9). https://doi.org/10.3390/ijms17091543
- 29.Disibio G, French SW (2008) Metastatic patterns of cancers: results from a large autopsy study. Arch Pathol Lab Med 132(6):931–939. https://doi.org/10.1043/1543-2165(2008)132[931:MPOCRF]2.0.CO;2 PubMedGoogle Scholar
- 30.Schrama JG, Baars JW, Holtkamp MJ, Schornagel JH, Beijnen JH, Rodenhuis S (2001) Phase II study of a multi-course high-dose chemotherapy regimen incorporating cyclophosphamide, thiotepa, and carboplatin in stage IV breast cancer. Bone Marrow Transplant 28(2):173–180. https://doi.org/10.1038/sj.bmt.1703105 CrossRefPubMedGoogle Scholar